Select a Community
Are you sure you want to trigger topic in your Anconeus AI algorithm?
You are done for today with this topic.
Would you like to start learning session with this topic items scheduled for future?
neuropathy
4%
121/2840
hearing loss
3%
72/2840
pulmonary fibrosis
118/2840
cardiac toxicity
88%
2488/2840
liver cirrhosis
1%
23/2840
Select Answer to see Preferred Response
Doxorubicin is an anthracycline antibiotic commonly used in oncological protocols to treat malignancies in children. It is a cytostatic agent and its cardiotoxicity is well known as shown in the cited study by Elbl et al, which found a 7% incidence of cardiotoxicity. Acute cardiotoxicity is rare but as patients live longer there is the possibility of delayed myocardial damage to a degree that depends on the cumulative dose of the agent. Compromised myocyte growth may eventually lead to a thinning of the wall of the left ventricle. This may lead to chamber dilation and the development of cardiomyopathy. Dexrazone is a drug that may be protective against the cardiac effects of doxorubicin. The use of dexrazone is reviewed in the reference by Wiseman et al.
2.8
(27)
Please Login to add comment